R&D Why UCB bet a billion dollars on cell therapy for epilepsy UCB's chief science officer spoke to pharmaphorum about why Neurona's in-development cell therapy could be a game changer for epilepsy treatment.
News UCB cuts $1.15bn deal to buy epilepsy biotech Neurona UCB has dipped its toe into the M&A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy.
News MoonLake secures $500m for lead drug, plus other financings MoonLake secures $500m in financing for lead inflammatory disease drug sonelokimab while AIRNA, Atsena, and Neurona complete $100m+ private rounds.
News Iambic prices its IPO, seeking to raise up to $160m AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.